Company Analysis: Sharps Technology Inc. (STSS)

Introduction

Sharps Technology Inc. is a medical device and pharmaceutical packaging company that specializes in the design, manufacturing, and commercialization of safety syringe products. The company is headquartered in Melville, New York, and operates a manufacturing facility in Hungary. Sharps Technology seeks to address global healthcare challenges through innovative solutions, particularly in drug delivery systems.

Corporate Structure

• Employee Count: 51-200 employees
• Key Personnel:
  • Paul Danner (Business Executive)
  • Braden Miller (VP of Product and Program Management)
  • Soren Christiansen (Chairman)
  • Jeremy Gingerich (Injection Molding Process Engineer)

The company operates in an ISO-certified and FDA-cleared facility, ensuring compliance with US regulatory and WHO guidelines.

Recent Developments and News

1. Initial Purchase Order: On April 30, 2025, Sharps Technology announced a $400,000 purchase order from a U.S. leader in IV flushing solutions. This order marks the first commercial revenue under a previously announced $50 million supply agreement for approximately 500 million customized 10mL SoloGard syringes over a five-year period.

2. Reverse Stock Split: On April 24, 2025, Sharps Technology announced a 1-for-300 reverse stock split effective April 27, 2025. This action aims to comply with the minimum bid price requirement for maintaining its listing on the Nasdaq.

3. Financial Filings: Sharps Technology has filed several 8-K reports with the SEC, including updates on compliance with listing requirements and significant events.

Financial and Strategic Aspects

• Stock Data:

  • Ticker: STSS
  • Current Price: $6.54
  • Price Change: +30.80%
  • Volume: 4,561,907 shares
  • Market Cap: Approximately $81.67 million

• Financial Performance: The company reported a net income attributable to common shareholders of -$9.3 million, with a return on assets of -62.99% and a return on equity of -187.23%. The company has a total cash position of $864.04k and a total debt-to-equity ratio of 188.55%.

• Strategic Initiatives: Sharps Technology is focused on expanding its product line, including pre-filled syringe designs and customized delivery systems. The company has invested in advanced manufacturing technologies to enhance production efficiency and meet anticipated demand.

Market Position and Industry Context

Sharps Technology operates within the medical device manufacturing sector, specifically targeting the syringe market. The company’s products, such as the Sharps Provensa™ safety syringes, are designed to minimize needlestick injuries and reduce waste in healthcare settings. The World Health Organization has forecasted a significant syringe shortage, which presents both challenges and opportunities for companies like Sharps Technology.

The company’s strategic partnerships and recent purchase orders indicate a growing market presence and potential for revenue generation. However, the financial metrics indicate that the company is currently operating at a loss, which may impact its long-term sustainability if not addressed.

TL;DR

As of April 30, 2025, Sharps Technology Inc. (STSS) has secured a $400,000 purchase order under a $50 million supply agreement for SoloGard syringes. The company executed a 1-for-300 reverse stock split to maintain its Nasdaq listing. Financially, Sharps reported a net loss of $9.3 million and a market cap of approximately $81.67 million. The company is focused on expanding its product offerings and enhancing manufacturing capabilities to meet market demand.